Paul G. Richardson

HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody – Primary and Subgroup Analysis

Introduction / Background / Significance: Background: Despite improvements in outcomes for patients with MM, most will relapse, and survival is poor (Kumar et al. Leukemia. 2017;31:2443)....

Paul G. Richardson ;

10/19/2020

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis

Purpose of the Study: Daratumumab (DARA), a human CD38 mAb, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for MM. In phase 3 studies, DARA-based regim...

Larry D. Anderson Jr.;

Daniela Hoehn ;

Nitya Nathwani ;

Thomas S. Lin ;

Nina Shah ;

Paul G. Richardson ;

Yvonne A. Efebera ;

Caitlin L. Costello , MD;

Andrzej Jakubowiak ;

Tanya M. Wildes ;

Ajai Chari , MD;

Robert Z. Orlowski ;

Peter M. Voorhees , MD;

Kenneth G. Shain ;

Johnathan L. Kaufman ;

Ander J. Cowan ;

Jacob Laubach ;

Sean Murphy ;

Douglas W. Sborov ;

Yana Lutska ;

Brandi Reeves ;

Huiling Pei ;

Cesar Rodriguez ;

Jon Ukropec ;

Rebecca Silbermann ;

Jessica Vermeulen ;

Luciano J. Costa ;

Carla de Boer ;

10/22/2019

OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide

Purpose of the Study: Only 20%-30% of patients with relapsed/ refractory multiple myeloma (RRMM) respond to the next line of treatment, and ultimately most will relapse. Melflufen is a li...

Pieter Sonneveld ;

Fredrik Schjesvold ;

Pawel Robak ;

Viktor Rossjey ;

Sosana Delimpasi ;

Ludk Pour ;

Wojciech Legic ;

Catriona Byrne ;

Galina Salogub ;

Jiri Minarik ;

Johan Harmenberg ;

Paul G. Richardson ;

Eva Nordstrom ;

10/22/2019

Updated Efficacy and Safety of Melflufen in Patients with Relapsed/ Refractory Multiple Myeloma Refractory to Daratumumab and/or Pomalidomide: HORIZON (OP-106)

Purpose of the Study: Despite advances in therapy, MM remains incurable. Patients with late-stage relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or daratumumab...

Hani Hassoun ;

Adrian Alegre ;

Christopher Maisel ;

Amitabha Mazumder ;

Jeffrey A. Zonder ;

Noemi Puig ;

John Harran ;

Sara Thuresson ;

Hanan Zubair ;

Albert Oriol ;

Agne Paner , MD;

Maxim Norkin ;

Johan Harmenberg ;

Paul G. Richardson ;

Michele Cavo ;

Alessandra Larocca ;

Xavier Leleu ;

Paula Rodriguez-Otero ;

Maria-Victoria Mateos ;

Joan Blade ;

10/22/2019

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;